ME00566B - Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač - Google Patents

Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač

Info

Publication number
ME00566B
ME00566B MEP-2008-855A MEP85508A ME00566B ME 00566 B ME00566 B ME 00566B ME P85508 A MEP85508 A ME P85508A ME 00566 B ME00566 B ME 00566B
Authority
ME
Montenegro
Prior art keywords
pde
inhibitor
dosage form
polyvinylpyrrolidon
excipient
Prior art date
Application number
MEP-2008-855A
Other languages
English (en)
French (fr)
Inventor
Rango Dietrich
Klaus Eistetter
Hartmut Ney
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27758398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00566(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002107160 external-priority patent/DE10207160A1/de
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME00566A publication Critical patent/ME00566A/xx
Publication of ME00566B publication Critical patent/ME00566B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Opisan je oblik za doziranje za oralno uzimanje PDE 4 inhibitora, čija je rastvorljivost mala. Oni sadrže PVP kao punilac.
MEP-2008-855A 2002-02-20 2003-02-19 Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač ME00566B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02003811 2002-02-20
DE2002107160 DE10207160A1 (de) 2002-02-20 2002-02-20 Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
PCT/EP2003/001650 WO2003070279A1 (en) 2002-02-20 2003-02-19 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
YU73604A RS52548B (en) 2002-02-20 2003-02-19 ORAL DOSAGE FORM CONTAINED BY PDE 4 INHIBITOR AS ACTIVE INGREDIENT AND POLYVINYL PYRILIDONE AS EXPIENT

Publications (2)

Publication Number Publication Date
ME00566A ME00566A (en) 2011-12-20
ME00566B true ME00566B (me) 2011-12-20

Family

ID=27758398

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-855A ME00566B (me) 2002-02-20 2003-02-19 Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač

Country Status (34)

Country Link
US (11) US7951397B2 (me)
EP (2) EP2258394B1 (me)
JP (1) JP4163120B2 (me)
KR (2) KR101386843B1 (me)
CN (2) CN102764242B (me)
AR (1) AR038527A1 (me)
AT (1) ATE550038T1 (me)
AU (1) AU2003206924B2 (me)
BR (1) BR0307739A (me)
CA (1) CA2475923C (me)
CY (2) CY1112811T1 (me)
DK (2) DK2258394T3 (me)
EA (1) EA008219B1 (me)
EC (1) ECSP045238A (me)
ES (2) ES2424634T3 (me)
GE (1) GEP20074079B (me)
HK (1) HK1077752A1 (me)
IL (3) IL162843A0 (me)
IS (1) IS7410A (me)
MA (1) MA27100A1 (me)
ME (1) ME00566B (me)
MX (1) MXPA04005759A (me)
MY (1) MY140561A (me)
NO (1) NO332844B1 (me)
NZ (1) NZ535197A (me)
PE (1) PE20030823A1 (me)
PL (1) PL226401B1 (me)
PT (2) PT2258394E (me)
RS (1) RS52548B (me)
SI (2) SI2258394T1 (me)
TN (1) TNSN04124A1 (me)
TW (1) TWI363636B (me)
UA (1) UA84266C2 (me)
WO (1) WO2003070279A1 (me)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
RS52908B (en) 2003-03-10 2014-02-28 Takeda Gmbh NEW PROCEDURE FOR OBTAINING ROFLUMILAST
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
MXPA05012302A (es) 2003-05-22 2006-01-30 Altana Pharma Ag Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5.
DE10350528A1 (de) * 2003-10-29 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CN102614176A (zh) 2005-04-19 2012-08-01 奈科明有限责任公司 用于治疗肺动脉高血压的罗氟司特
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
US20110160213A1 (en) * 2007-02-01 2011-06-30 Glenmark Pharmaceuticals, S.A. Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
JP5568139B2 (ja) 2010-10-22 2014-08-06 デウー シップビルディング アンド マリン エンジニアリング カンパニー リミテッド 液化天然ガスの貯蔵容器
AU2012215606B2 (en) 2011-02-07 2016-12-22 Scipharm Sarl Novel composition for the treatment of cystic fibrosis
BR112014002397B1 (pt) 2011-08-10 2021-08-03 Daiichi Sankyo Company, Limited Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida
CN102274222B (zh) * 2011-08-18 2013-04-10 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特药物组合物及其制备方法
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CA2861594A1 (en) * 2011-12-27 2013-07-04 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
CN103446070B (zh) * 2012-05-31 2016-06-22 天津康鸿医药科技发展有限公司 一种罗氟司特固体速释制剂及其制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103565806A (zh) * 2012-07-31 2014-02-12 江苏柯菲平医药有限公司 一种罗氟司特口服制剂及其制备方法
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
CN102871976A (zh) * 2012-09-29 2013-01-16 华润赛科药业有限责任公司 一种含有罗氟司特作为活性成分的片剂及其制备方法
CN102949370B (zh) * 2012-11-27 2018-05-04 贵州信邦制药股份有限公司 一种罗氟司特片及其制备方法和检测方法
CN103127011B (zh) * 2012-12-27 2014-11-26 深圳万乐药业有限公司 罗氟司特片及其制备方法
CN103330689A (zh) * 2013-03-31 2013-10-02 北京万全德众医药生物技术有限公司 一种含有罗氟司特的口腔崩解片
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP3043798A4 (en) * 2013-09-13 2017-04-12 Hetero Research Foundation Pharmaceutical compositions of roflumilast and process for preparation thereof
WO2015132708A1 (en) * 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
EP3174999A1 (en) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
WO2016063906A1 (ja) 2014-10-24 2016-04-28 久光製薬株式会社 プロドラッグ
WO2016120746A1 (en) * 2015-01-29 2016-08-04 Micro Labs Limited A pharmaceutical composition comprising roflumilast
CN106176639A (zh) * 2015-04-30 2016-12-07 四川科伦药物研究院有限公司 一种制备罗氟司特片的方法
RU2659206C2 (ru) * 2016-04-14 2018-06-28 Общество с ограниченной ответственностью "Технофарм" Состав и способ промышленного производства тритурации дигоксина (варианты)
CN106139161A (zh) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 一种罗氟司特包合物及其固体制剂
JP7019978B2 (ja) * 2017-06-30 2022-02-16 富士電機株式会社 設備管理システム、設備管理方法およびプログラム
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111643470A (zh) * 2020-04-30 2020-09-11 山东希尔康泰药业有限公司 罗氟司特薄膜包衣片制备工艺
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4024240A (en) * 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
NZ196700A (en) * 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
DE3308239A1 (de) 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
GB8415540D0 (en) 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
JPS61205208A (ja) 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS61205208U (me) 1985-06-12 1986-12-24
JPS625966A (ja) 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (en) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
JPH0249720Y2 (me) 1986-05-08 1990-12-27
US5286494A (en) 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4791117A (en) * 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
EP0266890A1 (en) 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
JP2656101B2 (ja) 1987-07-16 1997-09-24 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規ジアゾール
GB8717644D0 (en) * 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5011843A (en) 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
EP0368158A1 (de) 1988-11-07 1990-05-16 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Imidazopyridine
KR900014376A (ko) 1989-03-13 1990-10-23 후지사와 토모키치로 이미다조 피리딘 화합물 및 그것의 제조방법
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
DE59009351D1 (de) 1989-04-17 1995-08-03 Byk Gulden Lomberg Chem Fab Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3943385A1 (de) 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
WO1991014677A1 (fr) 1990-03-28 1991-10-03 Otsuka Pharmaceutical Co., Ltd. Derive de quinoline, medicament anti-ulcereux contenant ce derive et production de ce derive
JP2851117B2 (ja) 1990-03-30 1999-01-27 日清製粉株式会社 インドール誘導体およびそれらを有効成分とする抗潰瘍薬
JP2816227B2 (ja) 1990-03-30 1998-10-27 日清製粉株式会社 抗潰瘍薬
AU7754691A (en) 1990-04-27 1991-11-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (de) 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazine
JPH06501941A (ja) 1990-10-16 1994-03-03 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング アリールピリダジノン
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
WO1992012969A1 (en) 1991-01-29 1992-08-06 Smithkline Beecham Intercredit B.V. Salts of a 4-amino-3-acyl quinoline derivative and their use as inhibitors of gastric acid secretion
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
US5449676A (en) 1991-04-26 1995-09-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridazines
EP0587744B1 (en) * 1991-05-28 2003-07-16 McNEIL-PPC, Inc. Chewable drug-delivery composition
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
EP0609328B1 (de) * 1991-10-25 1999-04-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
GB9126438D0 (en) 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
GB9200607D0 (en) 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
GB9201693D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
AU3481593A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
JP3523275B2 (ja) 1992-03-26 2004-04-26 東光薬品工業株式会社 貼付剤
WO1993025517A1 (en) 1992-06-15 1993-12-23 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) * 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE59409983D1 (de) * 1993-04-22 2002-01-10 Byk Gulden Lomberg Chem Fab Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
DE4314963A1 (de) 1993-05-06 1994-11-10 Bayer Ag Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine
US5556863A (en) 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
US5747069A (en) 1993-08-10 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Percutaneously absorbable preparation
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
SE9401197D0 (sv) 1994-04-11 1994-04-11 Astra Ab Active compounds
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
DE59510131D1 (de) 1994-07-28 2002-05-02 Byk Gulden Lomberg Chem Fab Imidazopyridin-azolidinone
JP3031280B2 (ja) 1994-08-19 2000-04-10 東陶機器株式会社 便器洗浄装置
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
FR2746800B1 (fr) * 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
JP3031280U (ja) 1996-05-15 1996-11-22 サン トップ コンピューター システムズ コーポレーション 線性ｃｃｄバーコードの読取り装置
SK283162B6 (sk) 1996-05-20 2003-03-04 Darwin Discovery Limited Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
JP2001503766A (ja) 1996-11-12 2001-03-21 フアーマシア・アンド・アツプジヨン・アー・ベー 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法
BR9807399B1 (pt) 1997-02-17 2011-04-19 composição para o tratamento de sìndrome da angústia respiratória infantil (irds) ou sìndrome da angústia respiratória aguda (ards) compreendendo 3-(ciclopropilmetóxi)-n-(3,5-dicloro-4-piridinil)-4-(difl uorometóxi) benzamida e tensoativo do pulmão, e seu uso.
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
CN101255164A (zh) * 1997-05-28 2008-09-03 奥坦纳医药公司 稠合的二氢吡喃类化合物及其用途
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
HUP0001555A3 (en) 1997-10-30 2001-01-29 Altana Pharma Ag Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
IL136249A0 (en) * 1997-12-08 2001-05-20 Byk Gulden Lomberg Chem Fab Suppository containing an acid-labile active compound
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
WO1999056776A2 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
CA2338753C (en) 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
WO2000012078A1 (en) * 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
DE59909760D1 (de) 1998-08-31 2004-07-22 Altana Pharma Ag Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
TR200100805T2 (tr) * 1998-09-23 2001-08-21 Byk Gulden Lomberg Chemische Fabr�K Gmbh Tetrahidropiridoeterler
HUP0103947A3 (en) 1998-09-29 2002-06-28 Fujisawa Pharmaceutical Co Novel methanesulfonate salts of pyridopyrazine compound and crystals thereof and their pharmaceutical use
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
DE69938192D1 (en) 1998-11-03 2008-04-03 Nycomed Gmbh Imidazonaphthyridine
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
DE19858331A1 (de) 1998-12-17 2000-06-21 Boehringer Ingelheim Pharma Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
CA2364258C (en) 1999-03-10 2008-12-30 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
CN1126468C (zh) 1999-04-08 2003-11-05 王力田 一种黑玉米秸秆饮料及其制备方法
ATE240956T1 (de) 1999-04-17 2003-06-15 Altana Pharma Ag Haloalkoxy-imidazonaphthyridine
KR100328972B1 (ko) 1999-04-23 2002-03-20 서경배 피부 유용 활성성분을 함유한 화장료 또는 피부도포용 의약품 조성물의 제조방법 및 이러한 방법에 의해 제조된 화장료 또는 피부도포용 의약품 조성물
CA2372850C (en) * 1999-05-04 2011-01-18 Ulrich Kilian Synergistic combination comprising roflumilast and a pde-3 inhibitor
EA005803B1 (ru) 1999-06-07 2005-06-30 Алтана Фарма Аг Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
ES2310166T3 (es) 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
ATE320800T1 (de) * 1999-08-21 2006-04-15 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
KR100729836B1 (ko) 1999-10-25 2007-06-18 소니 가부시끼 가이샤 콘텐츠 데이터 관리방법
US7076437B1 (en) 1999-10-29 2006-07-11 Victor Levy Process for consumer-directed diagnostic and health care information
NZ518002A (en) * 1999-10-29 2004-01-30 Smithkline Beecham Corp Method for administering a phosphodiesterase 4 inhibitor
US6985188B1 (en) 1999-11-30 2006-01-10 Thomson Licensing Video decoding and channel acquisition system
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
SK10342002A3 (sk) 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4
US6379682B1 (en) * 2000-02-07 2002-04-30 Color Access, Inc. Clear water-in-oil emulsions
US20030207845A1 (en) * 2001-02-08 2003-11-06 Keating Elizabeth T. Method and compositions for treating an inflammatory disease
EP1261331A4 (en) * 2000-02-16 2005-01-05 Univ Nebraska Medical Ct METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
JP2004500404A (ja) * 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
EP1289961A1 (en) * 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
EP1161950A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2427814C (en) 2000-11-07 2009-06-02 Merck & Co., Inc. A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
CN100528232C (zh) 2000-12-07 2009-08-19 尼科梅德有限责任公司 包含酸不稳定活性成分的混悬液形式的药物制剂
CN100536844C (zh) 2000-12-07 2009-09-09 尼科梅德有限责任公司 包含酸不稳定活性成分的糊剂形式的药物制剂
CA2430829C (en) 2000-12-07 2010-06-22 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2002230217B2 (en) 2001-02-15 2005-02-17 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
WO2002069939A2 (en) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6702796B2 (en) 2001-03-26 2004-03-09 The Procter & Gamble Company Absorbent interlabial device having an improved tab
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
CA2448363A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
ZA200300833B (en) 2001-06-27 2004-02-10 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents.
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6756392B2 (en) * 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
JP4636486B2 (ja) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20040087653A1 (en) 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
US20030215498A1 (en) 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
NZ537308A (en) 2002-05-28 2009-09-25 Nycomed Gmbh Ophthalmological use of roflumilast for the treatment of diseases of the eye
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CN102755646A (zh) * 2002-07-19 2012-10-31 艾博特生物技术有限公司 TNF α相关疾病的治疗
US20030018071A1 (en) * 2002-08-09 2003-01-23 Rennard Stephen I. Method and compositions for treating fibrotic diseases
ATE360627T1 (de) 2002-08-10 2007-05-15 Altana Pharma Ag Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
US7329676B2 (en) 2002-08-29 2008-02-12 Nycomed Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
CN1688292A (zh) 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 掩味剂型及其制造方法
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
PT1567139E (pt) * 2002-11-27 2008-10-01 Nycomed Gmbh Nova combinação sinérgica compreendendo roflumilaste e formoterol
JP2006508993A (ja) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト ロフルミラスト及び（ｒ，ｒ）−ホルモテロールを含有する新規の相乗組合せ
WO2004052345A1 (en) 2002-12-11 2004-06-24 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
DE602004023478D1 (de) 2003-01-30 2009-11-19 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
RS52908B (en) 2003-03-10 2014-02-28 Takeda Gmbh NEW PROCEDURE FOR OBTAINING ROFLUMILAST
WO2004084896A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
MXPA05012302A (es) 2003-05-22 2006-01-30 Altana Pharma Ag Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5.
US20050026883A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20060228410A1 (en) * 2003-08-11 2006-10-12 Hubert Dumont Flavored taste-masked pharmaceutical formulation made using a one-step coating process
WO2005020961A1 (en) 2003-08-28 2005-03-10 Sandoz Ag Pharmaceutical composition comprising anticonvulsant with taste mask coating
WO2005026095A1 (en) 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
AU2004279438A1 (en) 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
JP2007509154A (ja) 2003-10-21 2007-04-12 ファルマシア・コーポレーション ホスホジエステラーゼ４阻害剤と組み合わせたシクロオキシゲナーゼ−２阻害剤による呼吸器炎症のの治療または予防のための方法およびその組成物
US20070111995A1 (en) 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
US7562356B2 (en) * 2004-09-22 2009-07-14 Hewlett-Packard Development Company, L.P. Automatically resolving patch dependencies for a path bundle
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US7884059B2 (en) * 2004-10-20 2011-02-08 Afton Chemical Corporation Oil-soluble molybdenum derivatives derived from hydroxyethyl-substituted Mannich bases
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006094640A2 (en) 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
US7745646B2 (en) 2006-07-07 2010-06-29 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of PDE4
USD580547S1 (en) * 2007-07-31 2008-11-11 Nycomed Gmbh Tablet
JP5271070B2 (ja) 2008-12-24 2013-08-21 エスアイアイ・プリンテック株式会社 ヘッドチップ、液体噴射ヘッド及び液体噴射装置
US20120052122A1 (en) 2010-08-26 2012-03-01 Nycomed Gmbh Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
BR112013028668A2 (pt) 2011-05-06 2017-01-24 Glaxosmithkline Llc formulações de paracetamol de liberação sustentada
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure

Also Published As

Publication number Publication date
MA27100A1 (fr) 2004-12-20
ME00566A (en) 2011-12-20
RS73604A (en) 2007-02-05
TNSN04124A1 (en) 2007-03-12
US20140031397A1 (en) 2014-01-30
KR101386843B1 (ko) 2014-04-17
NO20043904L (no) 2004-11-11
TWI363636B (en) 2012-05-11
US20110251244A1 (en) 2011-10-13
RS52548B (en) 2013-04-30
NZ535197A (en) 2006-11-30
ES2384378T3 (es) 2012-07-04
UA84266C2 (uk) 2008-10-10
AU2003206924B2 (en) 2008-11-13
PL226401B1 (pl) 2017-07-31
IL237196A0 (en) 2015-03-31
EP1478399A1 (en) 2004-11-24
NO332844B1 (no) 2013-01-21
MXPA04005759A (es) 2004-09-10
CA2475923A1 (en) 2003-08-28
HK1077752A1 (en) 2006-02-24
US20140031396A1 (en) 2014-01-30
AU2003206924A1 (en) 2003-09-09
CY1114210T1 (el) 2016-08-31
KR20040084926A (ko) 2004-10-06
EA008219B1 (ru) 2007-04-27
US7951397B2 (en) 2011-05-31
CY1112811T1 (el) 2016-02-10
US9468598B2 (en) 2016-10-18
ES2424634T3 (es) 2013-10-07
US20110060016A1 (en) 2011-03-10
AR038527A1 (es) 2005-01-19
IL162843A0 (en) 2005-11-20
EP2258394A1 (en) 2010-12-08
US20060269600A1 (en) 2006-11-30
PT2258394E (pt) 2013-07-23
WO2003070279A1 (en) 2003-08-28
US20130345265A1 (en) 2013-12-26
JP2005517724A (ja) 2005-06-16
JP4163120B2 (ja) 2008-10-08
US8431154B2 (en) 2013-04-30
US20150290178A1 (en) 2015-10-15
IS7410A (is) 2004-08-18
ECSP045238A (es) 2004-09-28
KR20100103729A (ko) 2010-09-27
PT1478399E (pt) 2012-05-30
SI1478399T1 (sl) 2012-07-31
TW200303768A (en) 2003-09-16
PE20030823A1 (es) 2003-10-11
GEP20074079B (en) 2007-03-26
DK1478399T3 (da) 2012-06-25
SI2258394T1 (sl) 2013-09-30
BR0307739A (pt) 2005-01-25
MY140561A (en) 2009-12-31
IL162843A (en) 2015-03-31
EP1478399B1 (en) 2012-03-21
US20150290179A1 (en) 2015-10-15
CA2475923C (en) 2013-06-18
EA200401019A1 (ru) 2005-04-28
CN102764242B (zh) 2016-09-07
DK2258394T3 (da) 2013-08-19
CN1635909A (zh) 2005-07-06
US20150290180A1 (en) 2015-10-15
EP2258394B1 (en) 2013-05-15
PL370595A1 (en) 2005-05-30
CN102764242A (zh) 2012-11-07
CN1635909B (zh) 2012-09-05
KR101253033B1 (ko) 2013-04-11
US20130131123A1 (en) 2013-05-23
US20050159492A1 (en) 2005-07-21
ATE550038T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
ME00566B (me) Oralno doziranje oblika koji sadrži pde4 inhibitor kao aktivni sastojak i polivinil piridon kao prihvatač
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
RS54258B1 (en) SRC / ABL INHIBITOR FORMULATIONS
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
UA84277C2 (ru) Композиция трамадола с пролонгированным высвобождением с 24-часовым действием
HK1076605A1 (en) Formulations
HK1096034A1 (en) A solid dosage form comprising a fibrate
HK1101355A1 (en) Sustained-release tramadol formulations with 24-hour efficacy 24
MEP10808A (en) Solid drug for oral use
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
EA200600377A1 (ru) Новая композиция
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
DK1109538T3 (da) Antiinflammatoriske farmaceutiske formuleringer
ES2171749T3 (es) Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.
CU23370A3 (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
ATE259802T1 (de) Verbindungen mit antithrombotischer wirkung
TH59375A3 (th) สูตรผสมทางเภสัช ที่ซึ่งการปลดปล่อยออกได้ถูกควบคุม
HK1092699A1 (en) Pharmaceutical compositions of lavendustin